Page 25 - 期货和衍生品行业监管动态(2025年5月刊)
P. 25

期货和衍生品行业监管动态




                   月 21 日前提交意见。


                        基于反馈结果,ESMA 将与各成员国监管机构共同评估是否需要通过特定监

                   管调整或澄清来加强投资者保护并提高散户对金融市场的参与度。


                   ESMA Asks Input on the Retail Investor Journey as Part of Simplification and

                   Burden Reduction Efforts (2025/5/21)


                        The European Securities and Markets Authority (ESMA), the EU’s financial

                   markets regulator and supervisor, has today launched a Call for Evidence (CfE) on the

                   retail investor journey under MiFID II.


                        The purpose of this CfE is to gather feedback from stakeholders to better

                   understand how retail investors engage with investment services, and whether

                   regulatory or non-regulatory barriers may be discouraging participation in capital

                   markets.


                        The CfE explores:



                           key retail market trends, such as the appeal of speculative products for
                            younger investors and the influence of social media on investment decisions;



                           the practical application of MiFID II requirements in areas such as

                            regulatory disclosures, assessment of suitability and appropriateness; and


                           additional areas such as the investor experience under the European

                            crowdfunding framework and broader reflections on how to strike the right

                            balance between investor protection and enabling informed risk-taking.


                        Alongside the CfE, ESMA also publishes a summary of the main points,

                   translated into all EU languages to facilitate responses from consumers and their

                   representatives.


                        Background


                        As part of broader efforts to support efficient simplification and burden reduction


                                                             13
   20   21   22   23   24   25   26   27   28   29   30